Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1
Active, not recruiting, industry sponsors, Rare and genetic disease, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
1 trial
Showing 1 to 1, recently updated first.
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active, not recruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT05164055 · 17 participants · Start Jul 11, 2022 · Primary completion Jun 30, 2027
Drug: Avalglucosidase alfa (GZ402666) · For: Glycogen Storage Disease Type II
Sites: Bordeaux, France; Brest, France; Clermont-Ferrand, France · 11 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.